Department of Periodontics and Oral Medicine and Michigan Center for Oral Health Research, University of Michigan, 1011 N. University Ave., Ann Arbor, MI 48109-1078, USA.
Adv Drug Deliv Rev. 2012 Sep;64(12):1310-9. doi: 10.1016/j.addr.2012.03.005. Epub 2012 Mar 10.
Reconstruction of complex craniofacial deformities is a clinical challenge in situations of injury, congenital defects or disease. The use of cell-based therapies represents one of the most advanced methods for enhancing the regenerative response for craniofacial wound healing. Both somatic and stem cells have been adopted in the treatment of complex osseous defects and advances have been made in finding the most adequate scaffold for the delivery of cell therapies in human regenerative medicine. As an example of such approaches for clinical application for craniofacial regeneration, Ixmyelocel-T or bone repair cells are a source of bone marrow derived stem and progenitor cells. They are produced through the use of single pass perfusion bioreactors for CD90+ mesenchymal stem cells and CD14+ monocyte/macrophage progenitor cells. The application of ixmyelocel-T has shown potential in the regeneration of muscular, vascular, nervous and osseous tissue. The purpose of this manuscript is to highlight cell therapies used to repair bony and soft tissue defects in the oral and craniofacial complex. The field at this point remains at an early stage, however this review will provide insights into the progress being made using cell therapies for eventual development into clinical practice.
重建复杂的颅面畸形是在创伤、先天缺陷或疾病情况下的一项临床挑战。细胞疗法的应用代表了增强颅颌面创伤愈合的再生反应的最先进方法之一。体细胞和干细胞都已被用于治疗复杂的骨缺损,并且在寻找最适合于人类再生医学中细胞疗法传递的支架方面取得了进展。作为用于颅面再生的临床应用的此类方法的一个例子,Ixmyelocel-T 或骨修复细胞是骨髓来源的干细胞和祖细胞的来源。它们是通过使用单次通过灌注生物反应器生产的,用于 CD90+间充质干细胞和 CD14+单核细胞/巨噬细胞祖细胞。Ixmyelocel-T 的应用已显示出在肌肉、血管、神经和骨组织再生方面的潜力。本文的目的是强调用于修复口腔和颅面复合体中的骨和软组织缺损的细胞疗法。该领域目前仍处于早期阶段,但本综述将提供对使用细胞疗法进行的进展的见解,以期最终发展为临床实践。